Description
Generic Version of Olaparib Available in India?
Olaparib is the generic name of the medication and is its international nonproprietary name. Olaparib is marketed under the brand name BDPARP among others.
Olaparib, sold under the brand name Brcarib, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.
In December 2014, olaparib was approved for use as a single agent by the European Medicines Agency (EMA) in the European Union and by the Food and Drug Administration (FDA) in the United States.
OLAPARIB is a chemotherapy drug. It targets specific enzymes within cancer cells and stops the cancer cell from growing. This medicine is used to treat certain kinds of ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.
Will this product be accessible across all regions of India?
The product – Brcarib (Olaparib) Tablets will be available across India on request. Olaparib is available in all the major cities in India – Delhi, Chandigarh, Jodhpur, Patna, Kolkata, Lucknow, Hyderabad, Chennai, Ahmedabad, Bangalore, and Pune. To get or place an order from Aark Pharmaceuticals, a pharma distributor in India, please call us at+91 9999156233, You can also make an inquiry by emailing us at sales@aarkpharma.co.in, sales@aarkpharma.com, WhatsApp: +91 9999156233.
List of available brand-name drugs in India for Olaparib Tablets
Branded Generic Drugs for Olaparib Tablets: Lynparza | BDPARP | Brcarib | Parbraze | Ribaxa | BRACANAT | Obrenza
NEWS / UPDATES
- FDA approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals LP) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based.
- FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer
- DCGI approved AstraZeneca’s Lynparza as a monotherapy for adjuvant treatment of patients with high-risk early breast cancer
- Recommendations of the SEC (Oncology) made in its 18 th/24 meeting held on 10.09.2024 at
CDSCO HQ New Delhi: - DCGI orders withdrawal of cancer drug Olaparib for certain treatments
